Antimicrobial Resistance & Pandemics: emerging threats


Madhukar Pai, MD, PhD
Director, McGill Global Health Programs



AMR




Biology



The Evolution of Bacteria on a "Mega-Plate" Petri Dish (Kishony Lab)

https://www.youtube.com/watch?v=plVk4NVIUh8

History of antibiotic discovery and concomitant development of antibiotic resistance.



Julian Davies, and Dorothy Davies Microbiol. Mol. Biol. Rev. 2010;74:417-433

Microbiology and Molecular Biology Reviews

ANTIBIOTIC RESISTANCE HOW IT SPREADS







Antibiotics are given to food producing animals and crops



Animals develop drugresistant bacteria in their gut



Drug-resistant bacteria reaches humans through food, the environment (water, soil, air) or by direct human-animal contact



Antibiotics are given to patients, which can result in drug-resistant bacteria developing in the gut Antibiotic resistance happens when bacteria change and become resistant to the antibiotics used to treat the infections they cause.







Drug-resistant bacteria spreads to other patients through poor hygiene and unclean facilities Drug-resistant bacteria spreads to the general public


Patient attends hospital or clinic

www.who.int/drugresistance

#AntibioticResistance



Bad Bugs, Few Drugs




Adapted from Monnet DL, 2004


Slide courtesy: Payal Patel



https://www.pbs.org/newshour/show/drug-companies-arent-making-new-antibiotics-economic-cure

AMR is now getting a lot of attention








HOW BIG IS THE PROBLEM?

Antimicrobial Resistance burden in 2050



We estimate that by 2050, 10 million lives a year and a cumulative 100 trillion USD of economic output are at risk due to the rise of drug-resistant infections if we do not find proactive solutions now

to slow down the rise of drug resistance. Even today, 700,000 people die of resistant infections every year.



WHO PRIORITY PATHOGENS LIST FOR R&D OF NEW ANTIBIOTICS

Priority 1: CRITICAL#

Acinetobacter baumannii, carbapenem-resistant

Pseudomonas aeruginosa, carbapenem-resistant

Enterobacteriaceae*, carbapenem-resistant, 3rd generation cephalosporin-resistant

Priority 2: HIGH

Enterococcus faecium, vancomycin-resistant

Staphylococcus aureus, methicillin-resistant, vancomycin intermediate and resistant

Helicobacter pylori, clarithromycin-resistant

Campylobacter, fluoroquinolone-resistant

Salmonella spp., fluoroquinolone-resistant

Neisseria gonorrhoeae, 3rd generation cephalosporin-resistant, fluoroquinolone-resistant

Priority 3: MEDIUM


Streptococcus pneumoniae, penicillin-non-susceptible

Haemophilus influenzae, ampicillin-resistant

Shigella spp., fluoroquinolone-resistant

Mycobacteria (including Mycobacterium tuberculosis, the cause of human tuberculosis), was not subjected to review for inclusion in this prioritization exercise as it is already a globally established priority for which innovative new treatments are urgently needed.

Antibiotic resistance prevalence and national per-capita income




Gross National Income Per Capita (2014 USD, log scale)

Lines represent predicted values with shaded regions showing 95% confidence intervals according to a linear regression model.



Antibiotic resistance prevalence and national per-capita income





CAUSES OF ANTIBIOTIC RESISTANCE



Antibiotic resistance happens when bacteria change and become resistant to the antibiotics used to treat the infections they cause.



Over-prescribing of antibiotics



Patients not finishing their treatment



Over-use of antibiotics in livestock and fish farming



Poor infection control in hospitals and clinics



Lack of hygiene and poor sanitation



Lack of new antibiotics being developed


www.who.int/drugresistance

#AntibioticResistance



ANTIBIOTIC USE IN HUMANS






The greater the volume of antibiotics used, the greater the chances that antibiotic-resistant populations of bacteria will prevail in the contest for survival of the fittest at the bacterial level.

Evidence from around the world indicates an overall decline in the total stock of antibiotic effectiveness: resistance to all first-line and last-resort antibiotics is rising.

Antibiotic consumption trends by income: 2000–2015






ANTIBIOTIC USE IN ANIMALS



Global Antimicrobial Consumption in Food Animals




Some Hot spots:

Southeast coast China
South coast of India, Mumbai, Delhi



Countries with Highest Antimicrobial consumption in Food Animals





WHAT ARE THE DRIVERS OF AMR? EXAMPLE OF INDIA



Social Aspects in India

Reasons for prescribing antibiotics:

Private Sector

- patient demand
- fear of clinical failure
- fear of losing patients
- economic incentives
- varying knowledge on antibiotics and antibiotic resistance

Public Sector

- Huge workload
- Lack of diagnostic facilities
- Pressure to use short-dated medicines



Social Aspects in India


General Public:

- self-medication
- access to antibiotics without prescription
- Utilizing pharmacies as source of healthcare
- lack of awareness of antibiotic resistance



Poor Environmental Sanitation

Population without access to improved sanitation facilities, 2015






Perfect conditions for emergence of Superbugs

HUMAN SECTOR

ANIMAL/AGRI SECTOR

Plant production



Inadequate waste management from human, agriculture, and pharma sector

Aquaculture

PHARMA SECTOR



DRUG-RESISTANT TB AS A CASE STUDY




DRUG-RESISTANT TUBERCULOSIS REMAINS A PUBLIC HEALTH CRISIS

IN 2018

ABOUT 0.5 MILLION PEOPLE FELL ILL WITH DRUG-RESISTANT TB*

ONLY ONE IN THREE
PEOPLE ACCESSED
TREATMENT



OF THOSE TREATED, ONLY 56% WERE TREATED SUCCESSFULLY

*The 95% uncertainty interval for the incidence of rifampicin-resistant TB is 420 000 - 560 000.

About 80% of these cases had multidrug-resistant TB.






Drug-resistant TB: hard to treat with low cure rates




A patient with MDR-TB must take

14,600 pills in two years.

If you stack that many pills end-to-end, the line would be as tall as a 30-story building.






Kendall E, et al. Int J TB Lung Dis 2019

TB treatments costs rise dramatically due to AMR

Treatment costs are much higher in HICs than in LMICs (e.g., 80x higher for TB—and 20x higher for MDR-TB—in the U.S. than in India



TB = Tuberculosis (infectious disease caused by bacteria)

MDR = Multidrug-resistant

XDR = Extensively drug-resistant; TB caused by bacteria that are resistant to some of the most effective anti-TB drugs

SOLUTIONS & STRATEGIES



TACKLING ANTIMICROBIAL RESISTANCE ON TEN FRONTS



Public awareness



Sanitation and hygiene



Antibiotics in agriculture and the environment



Vaccines and alternatives



Surveillance



Rapid diagnostics



Human capital



Drugs




Global Innovation Fund



International coalition for action





First team to successfully meet the criteria wins

The Longitude Prize is a £10m prize fund, with an £8m payout, that will reward a team of researchers who develop a point—of—care diagnostic test that will conserve antibiotics for future generations and revolutionise the delivery of global healthcare.

Next Longitude assessment deadline

(every four months)

itude Prize opened for submissions



CARB-X is investing more than \$500 million between 2016 and 2021 into the research and development of new antibiotics, vaccines, rapid diagnostics and other lifesaving products to tackle the global threat of drug-resistant bacteria

https://carb-x.org/

https://longitudeprize.org

Pandemics





THE TERRIFYING LESSONS OF A PANDEMIC SIMULATION



By Nicola Twilley June 1, 2018













A recent outbreak exercise held by the Johns Hopkins Center for Health Security revealed vulnerabilities that are hardwired into the American system.








http://www.centerforhealthsecurity.org/our-work/events/2018_clade_x_exercise/media

Pandemic: "epidemic ... over a very wide area and usually affecting a large proportion of the population"

https://academic.oup.com/jid/article/200/7/1018/903237


Global Examples of Emerging and Re-Emerging Infectious Diseases



Famous, historic pandemics


- 1347 to 1351 Black Death: remade the landscape of Europe; in a time when the global population was an estimated 450 million, at least 75 million are believed to have perished throughout the pandemic
- 1918 Spanish flu: mortality rate as high as one in five and an estimated one-third of the world population afflicted, as many as 50 million people are believed to have died.





Famous 'modern' plagues

- HIV: originated from non-human primates in the 1920s, recognized in humans in 1980s, and killed >35 million people
- Swine flu: One of the new strains was the H1N1 "swine flu" virus that originated in Mexico in 2009. The strain went on to kill more than 18,000 people around the world.





Seven reasons we're at more risk than ever of a global pandemic

By Meera Senthilingam, CNN

() Updated 2:21 PM ET, Mon April 10, 2017










More from CNN




All Blacks and England to wear poppies in 'special' match



Bill Nelson's campaign sues Florida secretary of state as














- 1. Growing populations and urbanization
- 2. Encroaching into new environments
- 3. Climate change
- 4. Global travel
- 5. Civil conflict
- 6. Fewer doctors and nurses in outbreak regions
- 7. Faster information



Ebola's Lessons

How the WHO Mishandled the Crisis

Laurie Garrett

"the global response to the rise of new pathogens has continued to be limited, uncoordinated, and dysfunctional. From SARS to MERS, H5N1 to H1N1 to H7N9, the story has been similar. Poor nations are unable to detect new diseases quickly and bring them swiftly under control. Rich nations generally show only marginal interest in outbreaks until the microbes seem to directly threaten their citizens, at which point they hysterically overreact. Governments look after their own interests, cover up outbreaks, hoard scarce pharmaceutical supplies, prevent exports of life-saving medicines, shut borders, and bar travel."

Lessons from the Ebola Outbreak in West Africa



POLICY FORUM

Toward a Common Secure Future: Four Global Commissions in the Wake of Ebola

Lawrence O. Gostin¹*, Oyewale Tomori², Suwit Wibulpolprasert³, Ashish K. Jha⁴, Julio Frenk⁵, Suerie Moon⁶, Joy Phumaphi⁷, Peter Piot⁸, Barbara Stocking⁹, Victor J. Dzau¹⁰, Gabriel M. Leung¹¹





Summary Points

- Four global commissions reviewing the recent Ebola virus disease epidemic response consistently recommended strengthening national health systems, consolidating and strengthening World Health Organization (WHO) emergency and outbreak response activities, and enhancing research and development.
- System-wide accountability is vital to effectively prevent, detect, and respond to future global health emergencies.
- Global leaders (e.g., United Nations, World Health Assembly, G7, and G20) should maintain continuous oversight of global health preparedness, and ensure effective implementation of the Ebola commissions' key recommendations, including sustainable and scalable financing.





BMJ 2018;362:k3254 doi: 10.1136/bmj.k3254 (Published 9 August 2018)



ANALYSIS

Global epidemics: how well can we cope?

Although numerous initiatives have been launched to improve global capacity to respond to major outbreaks of disease, worrying gaps remain, report **Jennifer Leigh and colleagues**

Jennifer Leigh DrPH candidate¹, Gabrielle Fitzgerald chief executive officer², Elvis Garcia DrPH candidate¹, Suerie Moon director of research³

¹Harvard T H Chan School of Public Health, Boston, MA, USA; ²Panorama Global, Seattle, Washington, USA; ³Global Health Centre, Graduate Institute of Geneva, Switzerland

Summary points

The west Africa Ebola outbreak in 2014-5 highlighted deficiencies in global capacity to respond

This year's Ebola outbreak in the Democratic Republic of Congo showed that some of those deficiencies have been addressed

However, more progress needs to be made related to preparedness, monitoring, and knowledge sharing

Overall leadership is lacking, leading to numerous unlinked initiatives rather than a functional global response

Stewardship beyond WHO is needed

Many funding promises have not been met as epidemics have fallen down the political agenda

Ring the alarm

868 SHARES

in SHARE

The next epidemic is coming. Here's how we can make sure we're ready.

By Bill Gates | April 27, 2018

"The 2014 Ebola outbreak was a stark reminder of how vulnerable our society is to epidemics of infectious diseases. We weren't ready then, and we're still not ready now—but we can be. We don't know when the next epidemic will strike, but I believe we can protect ourselves if we invest in better tools, a more effective early detection system, and a more robust global response system."



Post Ebola, the world responded

- New tools (e.g. Ebola vaccine, diagnostics)
- Global Health Security Agenda
- CEPI
- Pandemic Emergency Financing Facility

New tools for Ebola



Xpert Ebola on GeneXpert platform 100% sensitivity & 96% specificity





Corgenix ReEBOV Antigen Rapid Test Kit 100% sensitivity and 92% specificity

The Global Health Security Agenda (GHSA) was launched in February 2014 and is a growing partnership of over 64 nations, international organizations, and non-governmental stakeholders to help build countries' capacity to help create a world safe and secure from infectious disease threats and elevate global health security as a national and global priority.





https://www.ghsagenda.org/home




http://cepi.net/

Understanding Poverty / Topics / Pandemic preparedness and strengthening health systems

Pandemic Emergency Financing Facility

July 27, 2017



The World Bank Group, with the support of Japan, Germany and the World Health Organization, has developed the Pandemic Emergency Financing Facility (PEF), a quick-disbursing financing mechanism that provides a surge of funds to enable a rapid and effective response to a large-scale disease outbreak. Eligible countries can receive timely, predictable, and coordinated surge financing if affected by an outbreak that meets PEF's activation criteria. The PEF breaks new ground by providing the first-ever insurance for pandemic risk, offering coverage to all low-income countries eligible for financing under IDA.



From Ebola to Zika: international emergencies and the securitization of global health

viewing the response to international emergencies only through the limited prism of security would condemn global health to an infinite succession of periods of "war" interspersed with "truces" focused on surveillance systems, rather than confronting the causes of the epidemics, rooted in the social determinants of health. If the immediate responses are not accompanied by structural changes capable of promoting a radical reduction in inequalities, the question remains: who will truly be safe at the end of each "war"?



Deisy Ventura



Perspective

Politics and Pandemics

Ron Klain, J.D.

- Rising tide of isolationism and xenophobia a turn inward in many high-income nations, particularly the United States and European countries.
- 2. Growing tide of antiscientific thinking and resistance to Evidence-based medicine often associated with surging populism and manifesting in the rise of the antivaccination movement.
- 3. Disease-related danger from change

If there really was a new pandemic, is the world unified enough to fight it??

